What Synocrom Treats: Main Uses and Benefits

---

Symptomatic Relief for Osteoarthritis and Joint Discomfort

Synocrom is commonly used for the symptomatic treatment of osteoarthritis (OA), the primary degenerative joint disorder, which helps ease the overall symptom burden. It is relevant in conditions characterized by chronic discomfort and pain, such as gonarthrosis (knee OA). It is applied across domains where additional symptomatic support is needed in situations where patients experience symptoms related to physical discomfort and noticeable physiological strain. The product is commonly used in conditions such as osteoarthritis of the knee and hip, and may be relevant for other synovial joints.

Addressing Stiffness and Impaired Joint Mobility

The product may assist with managing symptom clusters that interfere with daily functioning and is relevant for managing symptoms that interfere with daily comfort, including stiffness and limited range of motion associated with joint degeneration. This treatment supports patients during episodes of heightened discomfort, contributing to improved comfort during periods when symptoms become more noticeable. It helps patients cope more steadily with symptom fluctuations, contributing to functional stability during symptomatic periods.

"The core benefit is supporting patients during episodes of heightened discomfort and assisting with functional stability."

Use When Conservative Therapy is Insufficient

Synocrom is commonly used when short-term symptomatic assistance is needed, often applied during phases when symptoms become more noticeable after simpler non-pharmacologic therapy or simple analgesics have failed to provide adequate relief. It is considered relevant in clinical settings that involve supportive symptom management, offering an intermediate, localized option for conditions presenting with significant symptomatic burden. It is used within therapeutic areas involving supportive management of the joint condition.

Quick Fact: Supports Joint Stiffness and Pain Management in Mild to Moderate OA.

Regulatory References

1. FDA Summary of Safety and Effectiveness Data

Eligibility Scope

Synocrom is established for use only in the adult population. The official regulatory profile strictly defines who may receive the intra-articular injection and who is expressly excluded, primarily based on the need for a sterile injection environment and established safety data.

Eligibility Status	Applicable Populations (Official Regulatory Statement)
Contraindicated	Patients with known hypersensitivity (allergy) to hyaluronate preparations. Individuals presenting with infections or skin diseases in the area of the injection site, including active knee joint infections.
Use Not Established	Pediatric patients (typically ≤ 21 years of age), pregnant women, and lactating women. For these groups, the official safety and effectiveness status has not been demonstrated in clinical studies.
Conditional Use	Use requires caution in patients with pre-existing chondrocalcinosis or inflammatory joint conditions such as Gout or Rheumatoid Arthritis; a physician must evaluate the joint for signs of acute inflammation prior to initiating treatment.

The regulatory basis for Synocrom defines eligibility through absolute contraindications related to the substance and the injection site, as well as mandatory limitations for specific population groups. The official status for use in children, pregnancy, and lactation is that safety and effectiveness have not been established.

The official interaction profile for Synocrom is primarily defined by local procedural and chemical constraints at the site of administration, consistent with its classification as a non-systemic viscosupplementation agent. No systemic drug-drug interactions, such as those involving metabolic enzymes (e.g., CYP450) or drug transporters, are formally documented in major government regulatory sources for this product class.

Procedural and Chemical Restrictions

A critical restriction in the regulatory labeling involves Quaternary Ammonium Salts (QAS), which are common ingredients in topical antiseptics and disinfectants. Co-administration of Synocrom with disinfectants containing QAS, such as Benzalkonium Chloride, is restricted because this combination results in a chemical incompatibility that causes the sodium hyaluronate solution to precipitate. Consequently, regulatory documents mandate that QAS-containing agents must not be used concomitantly for skin preparation immediately prior to the injection.

Co-administration Constraints

Official labeling also details constraints regarding co-administration with other substances directed into the joint space. The safety and effectiveness of Synocrom when used concurrently with other intra-articular injectables have not been formally established in regulatory data. This limitation constitutes an administration restriction, which is documented to preserve the product's integrity and intended function within the joint environment.

How Synocrom Works at the Biological and Cellular Level

Synocrom functions as a targeted inhibitor whose mechanism centers on disrupting fundamental cellular communication. Its primary targets include specific Receptor Tyrosine Kinases (RTKs) located on the cell surface and critical intracellular signaling proteins like PI3K and MEK. This action reduces the cell's ability to receive and transmit pro-growth and anti-apoptotic signals into its nucleus.

The drug specifically modulates the PI3K/Akt/mTOR and the Ras/MAPK signaling pathways. These interconnected cascades regulate cellular proliferation and anti-apoptotic processes. By inhibiting key kinases within these pathways, Synocrom modulates dysregulated, overactive signaling. The resulting physiological effect of pathway blockade is the induction of Cell Cycle Arrest (stoppage of cell division) and the promotion of Apoptosis (programmed cell death). This combined mechanistic action results in the reduction of cell proliferation and the induction of a programmed cell death state, which defines the drug's core physiological effect.

Official Instructions for Use

The administration of Synocrom is strictly governed by the product's official regulatory labeling, as it is a procedure that must be performed by a healthcare professional.

Administration Schedule and Route

Feature	Official Instruction
Route of Administration	Intra-articular injection (directly into the joint space).
Administering Personnel	Must be administered only by a physician or under their direct supervision.
Dosing Frequency	Typically involves multiple injections administered at one-week intervals.
Course Length	A full course of treatment usually consists of 3 to 5 injections.

The drug is provided in a ready-to-use, pre-filled syringe that is intended for single use only and must not be re-sterilized or re-used. The medication is an injectable product, making specific instructions regarding its timing in relation to meals not applicable.

Procedural and Safety Steps

Before the injection is administered, the official procedure requires that the healthcare provider strictly observes aseptic technique. This is critical to minimize the risk of joint infection. If the joint contains an excess of fluid (effusion), the provider may need to remove this fluid before the injection is given. The full contents of the single-use syringe are to be injected into the required joint space. The established weekly interval between doses must be adhered to until the scheduled number of injections is complete, thereby defining the structured use protocol for the medicine.

Research Evidence / Overview of Studies for Synocrom

---

Evidence for Symptomatic Relief in Osteoarthritis

Research for Synocrom was studied for its use in conditions characterized by fluctuating or episodic manifestations like osteoarthritis (OA), marked by outcomes related to physical discomfort. Randomized Controlled Trials (RCTs) and Systematic Reviews research examined how symptoms change over time by applying studies examining patient-reported experiences of pain. Findings describe patterns observed in the studies where individuals reported changes in their pain, though reviews show considerable variability and findings were mixed across different trials.

Research on Functional Capacity and Joint Mobility

Research examined studies that explored outcomes reflecting daily functioning or activity level. This research was observed in patients to determine changes in their physical function and ability to move their joints, focusing on stiffness and limited range of motion. This evidence contributes to the broader evidence landscape by providing context on functional outcomes. Research describes data reviewed by authorities, used in research exploring how symptoms change over time and how patients reported discomfort during activity.

---

Durability of Symptom Relief and Long-term Follow-up

The majority of evidence was observed in trials that span short- to intermediate-term follow-up durations, typically up to six months. Long-term effects are not fully established because follow-up durations were limited in the primary comparative trials. Certainty remains low regarding the durability or maintenance of symptomatic changes across extended periods.

Evidence in Specific Patient Groups

Research describes that the results apply only to the populations studied, primarily focusing on individuals with mild to moderate OA whose symptoms were severe enough that simpler conservative therapies had been insufficient. Data for certain groups remain insufficient, including patients with very advanced OA or specific comorbidities. The research does not determine whether an individual will respond similarly to the patterns observed in the studied groups.

What the Research Does Not Fully Address

A significant limitation is the inconsistency and heterogeneity (variability) across the many trials and reviews. The evidence quality varies across studies, making definitive conclusions about group patterns difficult. The research does not establish or examine the underlying structural progression of osteoarthritis. Additionally, comparative evidence is lacking in terms of clear, consistent findings when comparing the treatment to other conservative options.

Common questions about Synocrom (FAQ)

Q: Can Synocrom be used by people with a history of kidney problems?

Official regulatory documents define specific populations who should not use the product, known as contraindications. These restrictions primarily focus on issues related to local joint infections, skin disease at the injection site, and known allergies to hyaluronate. Conditions like a history of kidney problems are typically not listed as absolute restrictions in the formal documentation for this locally-acting product.

---

Q: Is Synocrom safe to use if I am already taking other prescription pain relievers?

Regulatory documents state that no systemic drug-drug interactions are formally documented for Synocrom. This is because it is a local treatment injected directly into the joint space and does not act throughout the body like an oral pain reliever. Official guidance emphasizes the importance of sharing a complete list of all current medicines with the treating healthcare professional.

---

Q: Does alcohol consumption affect the use of Synocrom?

Official product information for Synocrom does not typically include warnings about systemic interactions with substances like alcohol. This is consistent with its route of administration, as it is delivered via intra-articular injection and is not designed to be absorbed throughout the body.

---

Q: I heard Synocrom can cause swelling. How common is that?

Official safety information classifies transient swelling, pain, and joint effusion (excess fluid) at the injection site as common local reactions. Official data indicates these local reactions are typically transient. This information is based on the safety data reviewed by regulatory authorities.

---

Q: Are there concerns about dependence or addiction with Synocrom?

Synocrom is classified as a viscosupplementation agent and is not a controlled substance. Official regulatory documents contain no discussion regarding the potential for dependence or addiction related to the use of this product.

---

Q: What should I know about driving or operating machinery while using Synocrom?

Official product information advises patients to be aware of the possibility of common local side effects, such as pain or swelling, following the injection. If these local effects occur, they may temporarily affect the ability to perform certain activities, such as driving or operating machinery.

---

Q: Is Synocrom an anti-inflammatory drug?

The formal regulatory classification defines Synocrom as a Viscosupplementation Agent. Its primary mechanism of action is mechanical, restoring the essential lubrication and shock-absorbing functions within the joint. It is not classified as a traditional systemic anti-inflammatory drug.

---

Q: Are there any specific activities to avoid while using Synocrom?

Official post-procedure guidance describes limitations on strenuous or weight-bearing activities for a short period following the injection (e.g., 48 hours). This guidance is in place to support the treatment protocol.

---

Q: Is Synocrom considered a prescription-only medicine in most countries?

Synocrom is administered via intra-articular injection, a procedure that is intended to be performed only by a physician or qualified healthcare professional. Due to this specialized administration requirement, it is formally classified as a prescription-only medicine (or equivalent legal status) by regulatory bodies.

---

Q: Is the biofermentative origin important for people with allergies?

Official documentation specifies that the Sodium Hyaluronate in Synocrom is produced through biofermentation. This process ensures the product is of non-animal origin. This detail is included to inform patients, particularly those with known allergies related to animal-sourced products like rooster comb.

---

Q: Does Synocrom contain latex?

The official documentation for Synocrom explicitly details the nature and contents of the container and syringe components. This information confirms whether or not the syringe, cap, or packaging contains natural rubber latex. This information is included as a safety precaution for patients who may have an allergy.

---

Q: Does the time of day matter when using Synocrom?

Official instructions define the required treatment schedule by the interval between injections (e.g., once weekly). The regulatory documentation does not require the injection to be performed at a specific time of day, such as morning or evening.

How to Store and Dispose of Synocrom: Official Regulatory Information

Labeled storage temperature requirements:	Store between 0 C and 25 C.
Light/moisture protection requirements:	Must be protected from moisture.
Handling requirements:	Must be protected from frost (do not freeze). Do not re-sterilize the syringe after use.
Packaging-related storage rules (if applicable):	Do not use if the box is open/damaged or the syringe tip has been opened.
Disposal instructions:	The single-use syringe and any unused contents must be discarded after the procedure according to local medical waste regulations.

Official storage and disposal statements:

Synocrom must be stored within the temperature range of 0 C to 25 C and protected from freezing and moisture to ensure product stability and integrity. The product has a three-year shelf-life when these conditions are maintained, and it must not be used after the expiration date. As a sterile, single-use syringe, it must not be re-sterilized, and the package integrity must be checked prior to use. The used syringe and all unused solution must be discarded immediately according to established pharmaceutical waste protocols.